Nasopharyngeal Carcinoma
Conditions
Interventions
1:Abraxane combined with cisplatin, concurrent chemotherapy of cisplatin and IMRT
Sponsors
Nasopharyngeal Carcinoma Department of Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Histologic diagnosis of nasopharyngeal carcinoma; 2. Aged between 18 and 60 years; 3. T3-4N0-1M0,T1-4N2-3M0(UICC 7th edition); 4. Laboratory parameters: Bone marrow function: WBC>=4.0*10^9/L, ANC>=1.5*10^9/L; PLT >=100*10^9/L; HB>=90g/L; Hepatic function: STB, CB<=ULN*1.5; ALT and AST<=ULN*1.5; Renal function: Cr<=ULN; Coagulation functionPT INR)<=ULN*1.5; 5. Without the malignant tumor of other tissue (excluding cerical cancer, basal cell carcinoma or squamous carcinoma); 6. Without other anti-cancer therapy (including steroids); 7. Without other serious disease limitted in the trial; 8. Voluntary to participate and sign informed consent document.
Exclusion criteria
Exclusion criteria: 1. Distant metastases; 2. Previously treated (surgery, chemotherapy, radiotherapy, EGFR targeted therapy or immunotherapy); 3. Second malignancy within 5 years; 4. Precious therapy with an investigational agent; 5. Uncontrolled seizure disorder or other serious neurologic disease; 6. Allergic reaction (>=Grade III) to any drug including in this study; 7. Clinically significant cardiac or respiratory disease; 8. Creatinine clearance <30ml/min; 9. Drug or alcohol addiction; 10. Do not have full capacity for civil acts; 11. With severe complications or active infection; 12. Concurrent immunotherapy or hormone therapy for other diseases; 13. Pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Countries
China
Contacts
Public ContactXIANG GUO
Outcome results
None listed